An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
Bristol-Myers Squibb
Intensity Therapeutics, Inc.
National Cancer Institute (NCI)
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Lytix Biopharma AS
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)